ArticleScientific reports2025
Individual and community-level social determinant impact on HPV-differentiated nasopharyngeal carcinoma disparities in the USA.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Individual and community-level associations of social determinants with pituitary adenoma disparities in the US.Journal of neuro-oncology · 2026Article
- Understanding Cancer Health Disparities.Cancers · 2026Review
- EARLY LIFE-COURSE PATTERNS OF REGISTRY-DEFINED SUBSEQUENT CANCERS AFTER HPV-RELATED MALIGNANCIES IN A U.S. POPULATION-BASED COHORT.medRxiv : the preprint server for health sciences · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinomas (NPC) are malignancies that have seen growing burdens with human papilloma virus (HPV) infection. This investigation aims to characterize social determinant factor of health (SDoH) differences across HPV-differentiated NPC across the USA. NPC-patients with confirmed-HPV status between 2010 and 2018 from the Surveillance-Epidemiology-End Results (SEER) database were analyzed by cox-proportional and logistic regressions of age, sex, race-ethnicity, census-level rurality-urbanicity, and census-level Yost-Socioeconomic Status (SES)-Index measures to assess mortality, staging, and delayed-treatment differences. Among 820-HPV( -) and 402-HPV(+) NPCs, both NPC-cohorts displayed reduced overall mortality risk with younger age (HR 0.56, 95% CI 0.38-0.81; HR 0.57, 0.45-0.73) and higher risk with male sex (HR 1.71, 95% CI 1.11-2.64; HR 1.42, 95% CI 1.07-1.87). For HPV(-) only, Hispanic (HR 0.51, 95% CI 0.32-0.82) and Asian ethnicities (HR 0.44, 95% CI 0.33-0.58) reduced overall mortality risk, while low Yost-SES-Index increased it (HR 1.44, 1.14-1.87). For HPV( -) only, delayed treatment occurred with lower Yost-SES-Index (OR 1.97, 95% CI 1.16-3.42). Using the Yost-SES-Index and other individual/census-level SDoH, multilevel SDoH-analyses of HPV-differentiated NPC-patients display vast prognostic and treatment differences based on HPV-status. These present specific targets to prospectively and strategically address drivers of disparity with limited public health resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.